|
|
Vaccine Detail
|
NY-ESO-1, MAGE-A1, and MAGE-A3 Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: NY-ESO-1, MAGE-A1, and MAGE-A3 Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3) (NCT02332889)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This vaccine ismade from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs). (NCT02332889)
|
| Host Response |
|
|
| References |
NCT02332889: Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs [https://clinicaltrials.gov/study/NCT02332889]
|
|
